InMed Pharmaceuticals Stock

INM

CA4576378091

Delayed Nasdaq 00:00:00 07/11/2026 +03			5-day change	1st Jan Change
15.56 ^USD	+17.79%		-4.54%	+46.79%

11-07	InMed Pharmaceuticals Completes Merger with Mentari Therapeutics	MT
11-06	InMed Pharmaceuticals Inc.(NasdaqCM:INM) dropped from NASDAQ Composite Index	CI

Valuation: InMed Pharmaceuticals

Market Cap	10.34M 9.27M 8.54M 7.76M 14.69M 969M 15.1M 102M 40.76M 519M 38.8M 37.98M 1.64B	P/E 2025	-0.39x	P/E 2026	-0.5x
Enterprise Value	8.1M 7.27M 6.7M 6.08M 11.51M 760M 11.83M 80.2M 31.95M 407M 30.41M 29.77M 1.29B	EV / Sales 2025	-1,305,915x	EV / Sales 2026	-
Free-Float	-	Yield 2025 *	-	Yield 2026	-

* Estimated data More valuation ratios

Latest news: InMed Pharmaceuticals

11-07	InMed Pharmaceuticals Completes Merger with Mentari Therapeutics	MT
11-06	InMed Pharmaceuticals Inc.(NasdaqCM:INM) dropped from NASDAQ Composite Index	CI
11-06	Mentari Therapeutics, Inc. completed the acquisition of InMed Pharmaceuticals Inc. in a reverse merger transaction.	CI
11-04	InMed Pharmaceuticals Inc. has Changed its Name to MENTARI THERAPEUTICS, INC	CI
11-03	InMed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2026	CI
09-09	InMed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI
09-09	InMed Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	CI
07-07	InMed Pharmaceuticals Amends Deal With Mentari Therapeutics	MT
05-25	InMed Pharmaceuticals Inc. - M&A Call
05-19	InMed Pharmaceuticals Inc. announced that it expects to receive $290 million in funding from a group of investors	CI
05-19	InMed Pharmaceuticals InMed shareholders are expected to own approximately 1.51% of combined company	RE
05-07	InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
04-30	Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification	RE

More news

Last Transcript: InMed Pharmaceuticals

InMed Pharmaceuticals Inc. - M&A Call

05-25

More transcripts

Analysts' recommendations: InMed Pharmaceuticals

16/05/22	Roth Capital Downgrades InMed Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $0.80 From $6	MT
29/11/21	HC Wainwright Starts InMed Pharmaceuticals at Buy With $6 Price Target	MT

More recommendations

Press Releases: InMed Pharmaceuticals

11-06	InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"	NE
11-05	InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation	NE
11-03	InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update	NE
11-03	InMed Announces Share Consolidation in Connection with Proposed Merger	NE
10-27	InMed Announces CVR Distribution Record Date in Connection with Proposed Merger	NE

More press releases

Mentari Therapeutics, Inc., formerly InMed Pharmaceuticals Inc., is a biotechnology company developing therapies for migraine prevention. The Company's lead programs target PACAP, a newly validated target that is mechanistically independent from calcitonin gene-related peptide (CGRP). Its pipeline includes MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing, and MT-002, an anti-CGRP and anti-PACAP bispecific antibody designed to inhibit these complementary pathways with the potential to deliver superior outcomes for people with incomplete response to CGRP-targeted therapies.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	$15.56	+17.79%	27,154
05/11/26	$13.21	-24.51%	32,864
04/11/26	$17.50	+4.17%	12,061
03/11/26	$16.80	+3.07%	17,483

Delayed Quote Nasdaq

More quotes

Markets		Quality
Nasdaq	INM	Delayed
CBOE	INM	Real-time
Deutsche Boerse AG	MWG0	Delayed
Börse Stuttgart	MWG0	Delayed
Boerse Muenchen	MWG0	Real-time

1 day	+17.79%
1 week	-4.54%
Current month	-2.75%
1 month	+14.41%
3 months	+5.85%
6 months	+139.38%
Current year	+46.79%

1 week	12.88	18.3
1 month	12.88	18.3
Current year	5.75	23.3
1 year	5.75	23.3
3 years	5.75	156.96
5 years	5.75	11,850
10 years	5.75	321,750.32

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/23/26 A	Adar1 Capital Management LLC	Buy	Company	4	0.0001%
10/19/26 A	Adar1 Capital Management LLC	Buy	Company	1,086	0.0198%
10/15/26 A	Adar1 Capital Management LLC	Buy	Company	984	0.0179%

	2025	2026
Net sales	4.94 4.43 4.09 3.71 7.02 463.41 7.22 48.91 19.49 248.28 18.55 18.16 784.89	-
Net income	-8.16M -7.32M -6.75M -6.13M -11.59M -765M -11.92M -80.77M -32.18M -410M -30.63M -29.98M -1.3B	-12.56M -11.26M -10.38M -9.43M -17.84M -1.18B -18.34M -124M -49.52M -631M -47.14M -46.14M -1.99B
Net Debt	-10.38M -9.31M -8.58M -7.79M -14.74M -973M -15.15M -103M -40.92M -521M -38.95M -38.12M -1.65B	-2.23M -2M -1.85M -1.68M -3.17M -209M -3.26M -22.11M -8.81M -112M -8.38M -8.21M -355M

InMed Pharmaceuticals Stock

Stocks

INM

CA4576378091

Valuation: InMed Pharmaceuticals

Chart: InMed Pharmaceuticals

Latest news: InMed Pharmaceuticals

Last Transcript: InMed Pharmaceuticals

Analysts' recommendations: InMed Pharmaceuticals

Press Releases: InMed Pharmaceuticals

Quotes and Performance

Price Extremes

Latest insider transactions

Financials

Company Profile

Quotes